REFERENCES
- Shen.L, Xie.X, Su.Y, Luo.C, Zhang.C and Zeng.B. Parathyroid Hormone
versus Bisphosphonates Treatment on Bone Mineral Density in
Osteoporosis Therapy: A Meta-Analysis of Randomized controlled
Trials. PLoS One A Peer-Reviewed Open Access Journal . 2011; 6
(10)
- Yang.Y, Zhang.X, Zhu.X, Zhang.L, Bao.M, Xian.Y, Wu.J, Mei.L, Li.P.
Comparison between Recombinant Parathyroid Hormone (1-34) and
elcatonin in treatment of primary osteoporosis. Asian Pacific
Journal of Tropical Medicine . 2015;79-84
- Lane.N. Epidemiology, etiology and diagnosis of osteoporosis. American
Journal of Obstetrics and Gynecology. 2006; 194: s3-s11.
- Tian, MD.L, Xang, Msc.R, Wei, MD.L, Liu, MD.J, Yang, MD.Y, Shao,
Msc.F, Ma, Msc.W, Li, Msc.T, Wang, Msc.Y, Guo, Md.T. Prevalence of
osteoporosis and related life style and Metabolic factors of
postmenopausal women and elderly men: A cross sectional study in Gansu
Province, North western of China. Medicine; October 2017, vol.96 (43);
pe 8294.
- Haris.S, Jahan.F, Afreen.A, Ahmed.H and Ahmed.Z. Osteoporosis among
Adult Pakistani Population Residing in Karachi Using Quantitative
ultrasound Technique. Community Medicine & Health Education. 2014;
4:4
- Elliot.M. Prevention and Management of Osteoporosis. The Journal
of Pharmacy Society of Wisconsin . 2010; 29-41.
- Liu.Y, Dvornyk.V, Lu.Y, Shen.H, Lappet.J, Recker.R and Deng.H. A Novel
Pathophysiological Mechanism for Osteoporosis suggested by an In Vivo
Gene Expression Study of Circulating Monocytes. The Journal of
Biological Chemistry. Vol.280 no.32 p.29011-29016.
- Lin.X, Xiong.D, Peng.Y, Sheng.Z, Wu.X, Wu.X, Wu.F, Yuan.L and Liao.E.
Epidemiology and Management of Osteoporosis in People’s Republic of
China: Current perspectives. Clinical Interventions in Aging .
2015; 10: 1017-1033.
- Dobbs.M, Buckwalter.J, Saltzman.C. “Osteoporosis the Increasing Role
of Orthopaedist.” The IOWA ORTHOPAEDIC JOURNAL. 1999; 19:
43-52.
- Faienza.M, Ventura.A, Marzano.F, Cavallo.L. Postmenopausal
Osteoporosis: The Role of Immune System Cells. Hindawi Journal
of Immunology Research . Vol.2013 (2013) p6.
- Sozen.T, Ozisik.L, basaran.N. An overview and management of
osteoporosis. European Journal of Rheumatology . Vol.4
(1); 2017 Mar.
- Mirza.F and Canalis.E. SECONDARY OSTEOPOROSIS: PATHOPHYSIOLOGY AND
MANAGEMENT. European Journal of Endocrinology . 2015 Sep; 17
(3): R131-R151.
- Miazgowski.T, Kleevekoper.M, Felsenberg.D, Stepan.J and Szulc.P.
Secondary Osteoporosis: Endocrine and Metabolic Causes of Bone Mass
Deterioration. Journal of Osteoporosis . Vol. 2012 (2012); 2
pages.
- Sie-Marie.L. OSTEOPOROSIS: PATHOPHYSIOLOGY AND BONE REMODELING.JOURNAL Society of Obstetricians and Gynecologists
Canada. December 1995; 17: 1205-09.
- Souza.M. OSTEOPOROSIS DIAGNOSIS AND TREATMENT. Revista
Brasileria de Ortopedia . 2011 May-Jun; 43(3): 2220-2229.
- Kostecra.M. The role of healthy diet in the prevention of osteoporosis
in postmenopausal period. Pakistan Journal of Medical Sciences .
2014 Jul-Aug; 30(4): 763-768.
- Cashman.K. Diet, nutrition and Bone health. The Journal of
Nutrition. Vol.137(11): 2507S-2512S
- Sweet.M, Sweet.J, Jeremiah.M, Galazka.S. Diagnosis and Treatment of
Osteoporosis. American Family Physician . Vol.79 (3);
2009: 193-200.
- Reid.I, Grainger.R. Prevention of Osteoporosis. Biomedical and
Pharmacology Journal. Issue 17: 6-13.
- Schrager.S. Osteoporosis Prevention in Primary Care. WISCONSIN
MEDICAL JOURNAL. 2003, Vol.102 (3): 52-55.
- Gabriele.P. Risk factor identification and prevention o osteoporosis
in primary care setting. Malta Medical Journal . 18(01): 40-45.
- Lin.J, Lane.J. Non pharmacologic Management of Osteoporosis to
Minimize Fracture Risk. Nature Clinical Practice Rheumatology. 2008;
4(1): 20-25.
- Cosma.F, Beur.S, LeBoff.M, Lewiecki.E, Tanner.B, Randall.S and
Lindsay.R. Clinician’s Guide to Prevention and Treatment of
Osteoporosis. Osteoporosis International . 2014; 25(10):
2359-3381.
- Gehrig.L, Lane.J and O’connor.M. Osteoporosis: Management and
Treatment strategies for Orthopedic Surgeons. The Journal of
Bone and Joint Surgery . 2008; 90: 1362-1374.
- Fleisch.H. Bisphosphonates in Osteoporosis. European Spine
Journal . 2003 Oct; 12 (suppl.2): s142-s146.
- Sinigaglia.L, Varenna.M and Casari.S. Pharmacokinetic Profile of
Bisphosphonates in the Treatment of Metabolic bone disorders.Clinical Cases in Mineral and Bone Metabolism . 2007 Jan-Apr;
4(1): 30-36.
- Russel.R, Rogers.M, Frith.J, Luckman.S, Coxon.F, Benford.H,
Croucher.P, Shipman.C and Flerisch.H. The Pharmacology of
Bisphosphonates and New Insights into Their Mechanism of Action.
Journal of Bone and Mineral Research . 1999; Vol. 14(suppl.2): 53-65.
- Byun.J, Jang.S, Lee.S, Park.S, Yoon.H, Yoon.B and Ha.Y. The Efficacy
of Bisphosphonates for Prevention of Osteoporotic Fractures. An Update
Meta-Analysis. Journal of Bone Metabolism . 2011 Feb; 24(1):
37-49.
- Kennel.K and Drake.M. Adverse Effects of Bisphosphonates: Implication
for Osteoporotic Management. Mayo Clinic proceedings . 2009 Jul;
84(7): 632-638.
- Hodsman.A, Bauer.D, Dempster,D, Dian.L, Hanley.D, Harris.S, Kendler.D,
McClung.M, Miller.P, Olszynski.W, Orwoll.E and Yuen.C. Parathyroid
Hormone and Teriperatide for the Treatment of Osteoporosis: A Review
of the Evidence and Suggested Guidelines for Its Use. Endocrine
Reviews . Aug 2005; 26(5): 688-703.
- Body.J, Gaich.G, Scheele.W, Kulkarni.P, Miller.P, Peretz.A, Dore.R,
Rotter.R, Papioannou.A, Cumming.D and Hodsman.A. A Randomized
Double-Blind Trial to Compare the Efficacy of Teriperatide
[Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in
Postmenopausal Women with Osteoporosis. The Journal of Clinical
Endocrinology and Metabolism. 87(10): 4528-4535.
- Stroup.J, P-kane.M and Abu-Baker.A. Teriperatide in the Treatment of
Osteoporosis. American Journal of Health System . Mar 15, 2005;
Vol.65 (6): 532-539.
- VW B, J Br, The role of nutrition in osteoporosis. Br j biomed
science. 1994; 51(3):228-40.
- AJ. C and FJ. R. Review of risk factors for osteoporosis with
particular reference to possible etiological role of dietary salt.DOI . 2000; 38(2-30); 237-253.